Australia's BLS Pharmaceuticals extends gains on upbeat outlook, strong results
01/09/2026 04:25
BUZZ-Australia's BLS Pharmaceuticals extends gains on upbeat outlook, strong results ** Shares of Australia's BLS Pharmaceuticals BLS.AX rise as much as 13.2% to A$1.200, hitting their highest level since December 2017
** Stock extends gains after the pharmaceutical firm on Monday reported strong FY26 results and forecast robust revenue growth for FY27
** Co posted full-year revenue of A$74.2 million ($53.20 million), up 161% Y/Y
** BLS expects FY27 revenue between A$105 million and A$115 million, implying growth of about 42% to 55% from FY26
** Co posted net profit after tax of A$15.4 million, up from A$4.9 million in FY25
** YTD, stock up 169.1%
($1 = 1.3949 Australian dollars)
(Reporting by Paridhi Minda in Bengaluru)
Recent news on BLS Pharmaceuticals
See all newsBrief: BLS Pharmaceuticals Posts Q1 FY27 Revenue A$26.7M
Brief: BLS Pharmaceuticals Reports Record Q1 FY27 Revenue Of A$26.7 Million
Australia's BLS Pharmaceuticals extends gains on upbeat outlook, strong results
Brief: BLS Pharmaceuticals Sees FY27 Adjusted. EBITDA Margin 23% - 26%
Brief: BLS Pharmaceuticals Posts FY Net Profit After Tax Of A$15.4 MLN